Drug profile · INN
cefiderocol sulfate tosylate
FETROJA
cefiderocol sulfate tosylate (FETROJA) is a bacterial penicillin-binding protein inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — cefiderocol sulfate tosylate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
cefiderocol sulfate tosylate (FETROJA) is a bacterial penicillin-binding protein inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cefiderocol sulfate tosylate?
cefiderocol sulfate tosylate (FETROJA) is a bacterial penicillin-binding protein inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for cefiderocol sulfate tosylate?
FETROJA is a marketed brand name for cefiderocol sulfate tosylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cefiderocol sulfate tosylate?
cefiderocol sulfate tosylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.